diphtheria, tetanus, and acellular pertussis vaccine + hepatitis B vaccine

**Diphtheria, tetanus, and acellular pertussis vaccine + hepatitis B vaccine** is a combination vaccine, often formulated as a pentavalent or hexavalent product (e.g., including inactivated poliovirus and sometimes Haemophilus influenzae type b conjugate), designed for primary immunization of infants against diphtheria (caused by Corynebacterium diphtheriae toxoid), tetanus (Clostridium tetani toxoid), pertussis (acellular components targeting pertussis toxin, filamentous hemagglutinin, and pertactin), and hepatitis B (recombinant HBsAg). It induces protective antibody responses, with seroprotection rates typically exceeding 95-100% post-primary series and booster doses for all components, as demonstrated in clinical trials administered at 2, 4, and 6 months. Developed by GlaxoSmithKline (Pediarix) and Merck/Sanofi Pasteur (Vaxelis), it is administered intramuscularly starting at 6 weeks of age in HBsAg-negative mothers' infants, contributing to high vaccination coverage and disease control, with a well-established safety profile from over a decade of post-marketing data.[1][2][3][6][7]

Brand names

PediarixVaxelis

Other names

DTaP-HepB vaccineDTaP-IPV-HepB vaccine